# EDGAR Filing Document

**Accession Number:** 0001463414
**File Stem:** 0001213900-25-090602
**Filing Date:** 2025-9
**Character Count:** 9531
**Document Hash:** 235d9856551539532cf9d6b03a1ffad4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-090602.hdr.sgml**: 20250923

**ACCESSION NUMBER**: 0001213900-25-090602

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250808

**FILED AS OF DATE**: 20250923

**DATE AS OF CHANGE**: 20250923

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mazur Leonard L
- **CENTRAL INDEX KEY:** 0001463414

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38174
- **FILM NUMBER:** 251333668

**MAIL ADDRESS:**
- **STREET 1:** C/O CITIUS PHARMACEUTICALS, INC.
- **STREET 2:** 11 COMMERCE DRIVE, 1ST FLOOR
- **CITY:** CRANFORD
- **STATE:** NJ
- **ZIP:** 07016
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Citius Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001506251
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 273425913
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**BUSINESS ADDRESS:**
- **STREET 1:** 11 COMMERCE DRIVE
- **STREET 2:** 1ST FLOOR
- **CITY:** CRANFORD
- **STATE:** NJ
- **ZIP:** 07016
- **BUSINESS PHONE:** (908) 967-6676

**MAIL ADDRESS:**
- **STREET 1:** 11 COMMERCE DRIVE
- **STREET 2:** 1ST FLOOR
- **CITY:** CRANFORD
- **STATE:** NJ
- **ZIP:** 07016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Trail One, Inc.
- **DATE OF NAME CHANGE:** 20110314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TrailOne, Inc.
- **DATE OF NAME CHANGE:** 20101119

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mazur Leonard L<br><sub>(Last) (First) (Middle)</sub><br>C/O CITIUS PHARMACEUTICALS, INC.<br>11 COMMERCE DRIVE, 1ST FLOOR<br><sub>(Street)</sub><br>CRANFORD, NJ 07016<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-08-08 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Citius Pharmaceuticals, Inc. [ CTXR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 410214 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Warrant to Purchase Common Stock<sup>(1)</sup> | $28.75 | 2025-08-08 |  | D<sup>(1)</sup> |  |  | 125490 | <sup>(1)</sup> | 2025-08-14 | Common Stock | 125490 | <sup>(1)</sup> | 0 | D |  |
| Warrant to Purchase Common Stock<sup>(1)</sup> | $28.75 | 2025-08-08 |  | A<sup>(1)</sup> |  | 125490 |  | <sup>(1)</sup> | 2026-08-14 | Common Stock | 125490 | <sup>(1)</sup> | 125490 | D |  |
| Warrant to Purchase Common Stock<sup>(2)</sup> | $19.25 | 2025-08-08 |  | D<sup>(2)</sup> |  |  | 89388 | <sup>(2)</sup> | 2025-09-27 | Common Stock | 89388 | <sup>(2)</sup> | 0 | D |  |
| Warrant to Purchase Common Stock<sup>(2)</sup> | $19.25 | 2025-08-08 |  | A<sup>(2)</sup> |  | 89388 |  | <sup>(2)</sup> | 2026-09-27 | Common Stock | 89388 | <sup>(2)</sup> | 89388 | D |  |
| Stock Option (Right to Purchase Common Stock) | $9.50 |  |  |  |  |  |  | <sup>(3)</sup> | 2034-11-07 | Common Stock | 24000 |  | 24000 | D |  |
| Stock Option (Right to Purchase Common Stock) | $17.50 |  |  |  |  |  |  | <sup>(4)</sup> | 2033-10-10 | Common Stock | 22000 |  | 22000 | D |  |
| Stock Option (Right to Purchase Common Stock) | $31.25 |  |  |  |  |  |  | <sup>(5)</sup> | 2032-10-04 | Common Stock | 22000 |  | 22000 | D |  |
| Stock Option (Right to Purchase Common Stock) | $51.00 |  |  |  |  |  |  | <sup>(6)</sup> | 2031-10-11 | Common Stock | 26000 |  | 26000 | D |  |
| Stock Option (Right to Purchase Common Stock) | $50.00 |  |  |  |  |  |  | <sup>(6)</sup> | 2031-07-22 | Common Stock | 12000 |  | 12000 | D |  |
| Stock Option (Right to Purchase Common Stock) | $25.25 |  |  |  |  |  |  | <sup>(6)</sup> | 2030-10-06 | Common Stock | 8000 |  | 8000 | D |  |
| Stock Option (Right to Purchase Common Stock) | $16.75 |  |  |  |  |  |  | <sup>(6)</sup> | 2029-10-08 | Common Stock | 7000 |  | 7000 | D |  |
| Stock Option (Right to Purchase Common Stock) | $40.50 |  |  |  |  |  |  | <sup>(6)</sup> | 2028-09-04 | Common Stock | 6000 |  | 6000 | D |  |
| Stock Option (Right to Purchase Common Stock) | $86.25 |  |  |  |  |  |  | <sup>(6)</sup> | 2027-09-13 | Common Stock | 1600 |  | 1600 | D |  |

---

### Footnotes:

(1) The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately.

(2) The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately.

(3) The options were granted on November 7, 2024. The options vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

(4) The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

(5) The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

(6) The options are vested in full and exercisable immediately.

**Remarks:**
All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.

**Signature:** /s/ Alexander M. Donaldson, by power of attorney  
**Date:** 2025-09-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**